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Rapidly progressive glomerulonephritis (RPGN) with angeitis: Predic-
tive factors of renal outcome after the first month of treatment. C.
Dupre-Goudable, A. Modesto-Segonds, 0. Fritz, C. Soler, F. Oksman, D.
Durand, and J-M Suc, Service de Néphrologb CHU Ranguei Toulouse,
France. Forty-five patients with RPGN and angeitis were retrospectively
studied (micropolyarteritis: N = 28; Wegener syndrome: N = 8; isolated
pauci-immune glomerulonephritis: N = 9). The average age was 603 years
(± 2.2) and 63% were men, The aim of the study was to determine predictive
factors of renal response after the first month of treatment considering
histologic findings on renal biopsy specimen before treatment and the
evolution of plasma creatinine value before treatment, after one month of
treatment, and after one year. All patients presented with proteinuria,
microscopic hematuria, and severe renal failure: 14 patients needed hemo-
dialysis at admission; for the others mean plasma creatinine value was 700
gmol/liter. ANCA were positive when tested (N = 27): pANCA = 15/27;
cANCA = 9/27; p + c ANCA = 3/27. Renal biopsy specimen showed
glomerular damage in 82% of the patients, with crescentic necrotizing
glomerulonephritis in more than 50% of glomeruli. Glomerular fibrosis and
interstitial fibrosis were quantified in percentage of glomeruli or examined
renal tissue. Patients were separated into three groups: renal fibrosis > 50%
(N = 10), renal fibrosis between 50 and 25% (N = 17), and renal fibrosis C
25% (N = 18). Treatment consisted of an association of steroids and
cyclosphophamide plasma exchange (N = 11). Renal outcome was
considered for the patients treated at least one month, There was a significant
variation of plasma ereatinine value at the end of the first month. This
variation is independant of plasma creatinine value at admission. Hemodial-
ysis could be discontinued in 3 patients. The best response to treatment was
obtained in the patients whose renal biopsy specimen showed less than 25%
of renal fibrosis (plasma creatinine value < 300 gmollliter at the end of the
first month). For these patients plasma creatinine value remained at the same
level after one year, and plasma ereatinine value at one month appeared
predictive for plasma creatinine after one year. Thus the severity of renal
disease judged on plasma creatinine value is not predictive of response to
treatment. Moreover, hemodialysis is not pejorative to the outcome of
treatment. A precise evaluation of renal fibrosis appears to be the determin-
ing argument before starting initial treatment (particulary in old patients).
The response to treatment at the end of the first month must be considered
before deciding long-term immunosuppressive therapy in cases of isolated
renal injury.
Interaction between human lymphocytes and porcine endothelial cells:
An obstacle to xenotransplantation? B. Binnelé, G. Thibault, H. Nivet, P.
Bardos, and 1'. Lebranchu, Service de Néphrologie-Hémodialyse, CHRU
Bretonneau, and Laboratoire d'Jmmunologie, Faculté de Médecine, Tours,
France. In view of the lack of organs for human allogcneic transplantation,
xenotransplantation could be developed in the next few years. Xenotrans-
plantation is at present limited by hypcracute rejection and organ necrosis.
Nevertheless, once hypcracute rejection has been prevented, the xenograft
could be exposed to the cell-mediated reaction. Adhesion of human
peripheral blood lymphocytes (PBL) to porcine aortic endothelial cells
(PAEC) was studied. Basal adhesion of PBL to PAEC was 25.9 6.8%.
The stimulation of PAEC by human recombinant tumor necrosis factor-a
(TNF-a), 100 U/mI over 6 hours, increased PBL adhesion from 25.9
6.8% to 36.6 12.2% (P < 0.01). The TNF-a effect was time- and
concentration- dependent, and was maximal with 100 U/mI between 6
hours and 18 hours. Phenotypic analysis of PBL showed that the percent-
age of adhering cells is much higher in the CD3—CD16+ population than
in the CD3+CD16— population (63.5% vs. 7.5%, respectively). These
percentages increased after stimulation of PAEC by TNF-a (90% vs. 18%,
respectively). Finally, adhesion of PBL treated with an anti-CD49d
monoclonal antibody to PAEC, stimulated or not stimulated by TNF-a,
was decreased by 28.5 5.5% and 49.7 8.2%, respectively. We conclude
that PBL are able to bind to PAEC. The percentages of adhering PBL
increase when PAEC are stimulated by human TNF-a. This adhesion
preferentially involves CD3—CDI6+ cells. CD49d (a4 chain of integrins)
is involved in this adhesion, This cell interaction between human lympho-
cytes and porcine endothelial cells must be considered as a risk of cellular
rejection in xcnotransplantation.
Course of hemophagocytic histiocytic syndrome in renal transplant
patients. L. Rostaing, D. Durand, G. Fillola, F. Rigal-Huguet, ii Lloveras,
and J.M. Suc, Service de Néphrologie, Unite de Transplantation d'Organes;
Service d'Hématologie Biologique; and Service d'Hématologie Clinique,
CHU Purpan, Toulouse, France. Hemophagocytic histiocytie syndrome
(HHS), or maerophage activation syndrome, was initially described by
Risdall et al in 1979. In this paper we report two renal transplant patients
and one renal-pancreas transplant patient on quadruple immunosuppres-
sive therapy presenting HHS soon after transplantation (range: day 28 to
day 240). Symptoms included persistent high fever (3/3), jaundice (2/3),
splcnomegaly (1), and hepatomegaly (1). Biological signs were severe
pancytopenia (3/3), an increase of LDH (3/3), ASAT (3/3), triglycerides
(2/3), IL-2 soluble receptor (2/2), and hypofibrinogenemia (2/3). Bone
marrow aspiration results were always poor and showed activated macro-
phages with hemophagocytosis (platelets, erythroblasts, granulocytes). In
two eases HHS was related to infection: disseminated primary toxoplas-
mosis (1), cytomegalovirus/legionella pneumonia (1); in the remaining one
it was in a context of disseminated T cell lymphoma. The three patients
died despite supportive and specific therapy including recombinant gran-
ulocyte colony stimulating factor (2) and epipodophyllotoxin VP 16 (1).
We speculate as to whether the early use of VP 16 in HHS could have
changed the dramatic outcome of this disease.
Maintenance cyclosporin a monotherapy in primary cadaver renal
transplant: Complementary results of a multicentric study. 0. Touchard,
Th. Hauet, F. Cogny van Weydevelt (Angers), B. Hurault de Ligny (Caen), P.
Peyronnet (Limoges), Y. Lebranchu (Tours), 0. Toupance (Reirns), P.
N'lioye and Nt Busson, Service de Néphrologie CHU de Poitiers and France
Transplant, Département Informatique, France. Between August 1984 and
December 1989, 463 consecutive adult patients received a first cadaver
graft in 6 French transplantation centers. The initial immunosuppression
was sequential with ATG or ALG, azathioprine (Az), corticosteroid (Cs)
and cyclosporin (CsA) introduced at the end of ALG or ATG treatment.
When the renal function was stable, with crcatininemia (Cr) C 200
cxmol/liter and the preformed anti-HLA antibodies were C 25% and/or
the number of rejection episodes was C 1 the Cs treatment was progres-
sively stopped from 1.5 to 3 months. If the Cr level was still stable, Az was
gradually stopped from 3 to 12 months. The CsA doses were suited to
obtain a whole blood through level of CsA between 100 and 200 ng/ml
measured by RIA or HPLC. Results: CsA monotherapy (C5A mono) was
tried in 234 patients. The average time of exposure was 6.5 2months. In
January 1993 (minimal follow-up time 36 months; average follow-up time
60.5 4.5 months), 135 patients had not received Cs or Az: 58% of
patients were defined as low immunological risks and were included in
1242
Kidney Internationa4 Vol. 46 (1994), pp. 1242—1248
Abstracts
Société de Néphrologie
Bruxelles, Belgium
October 20—22, 1993
Abstracts 1243
CsA mono trial and 29% of the 463 were first grafts. The causes of 99
withdrawals from CsA mono were: 48 cases of rejection, 26 cases of CsA
renal toxicity and 25 other causes including five deaths and 4 non-
compliances. The average duration of CsA mono for these patients
withdrawn from CsA mono was 26 + 13 months. At the withdrawal time
from CsA mono, the average level of serum creatinine was 187 20
.tmol/liter. The renal function was stable for patients still under CsA mono
with an average level of Cr at the inclusion in the trial of 124 10
jtmol/liter against 129 10 mol/liter at the end of the follow-up time(average duration of CsA mono: 52 months 6 months). The predictable
parameters of CsA mono success were: older age of recipients (43.2 vs 37.8
years, P = 0.0014), absence of preformed anti-HLA antibodies (incidence
of anti-HLA antibodies 18.5 vs. 27.3%, P = 0.001), and good stable renal
function at the time of inclusion in CsA mono trial (serum creatinine =
124 10 vs. 145 34 itmol/liter, P = 0.001). Conclusion: CsA mono as
a maintenance treatment was successfully applied in 58% of low immu-
nological risk recipients of a first renal transplant. CsA mono trial had not
jeopardized the overall results of first graft with an actuarial survival of
90% and 73% at 6 years for patients and grafts, respectively.
Internalization of imidazoline compounds into isolated cells from
rabbit kidney proximal tubule and interaction with I and 12 imidazoline
sites. C. Gargalidis-Moudanos and A. Panni CNRS URA 1482, CHU
Necker, Paris, France. Imidazoline binding sites represent a new class of
proteins localized in the plasma membrane and in the mitochondria.
Based on their pharmacological profile, these sites were classified as I and
'2' displaying respectively high and low affinity for clonidine and rilmeni-
dine. Recent studies have suggested that some cs2 adrenergic ligands
having an imidazoline or imidazoline-like structure, such as clonidine,
rilmenidine, moxonidine or guanabenz, could regulate urine flow rate and
renal sodium excretion via interaction with imidazoline sites. In order to
identify the class of imidazoline sites involved in the tubular effects of
these ligands, we performed binding studies on isolated cells from rabbit
kidney proximal tubule, using [3H]idazoxan, which binds to both I and '2
binding sites. Saturation studies demonstrated a maximal density of
imidazoline sites of 848 193 fmol/mg of protein and a dissociation
constant of 4.7 1.8 n. Cell permeabilization with digitonin led to a 45%
decrease of the maximal binding of 3H]idazoxan, suggesting ligand
internalization. The remaining binding (55%) was distributed between
mitochondria and plasma membrane. Competition curves of [3H]idazoxan
binding by clonidine and rilmenidine on intact and sonicated cells were
biphasic, with high affinity (30% of the binding, clonidine 27 5 nM;
rilmenidine 7.3 1.3 nM) and low affinity components (70% of the
binding, clonidine 3737 548; rilmenidine 3386 845 nM). These results
demonstrate that: (1) rabbit kidney proximal tubule cells express both I
and '2 imidazoline binding sites; (2) imidazoline and imidazoline-like
compounds are internalized and found in three different compartments,
cytosol, plasma membrane and mitochondria; (3) clonidine and rilmeni-
dine selectively bind to I binding sites. These data suggest that, in rabbit
kidney proximal tubule, the non-adrenergic effects of clonidine and
rilmenidine on water and sodium transport could be mediated by the I
imidazoline sites.
Mid-term effects of low-phosphorus, low-protein diet on phosphocalcic
metabolism in advanced renal failure. C. Combe, and M Aparicio, Service
de Néphrologie, Hôpital Pellegrin, Bordeaux, France. Phosphorus (P1)
retention linked to chronic renal failure (CRF) favors secondary hyper-
parathyroidism (HPT). Reduction of Pi and protein (Pr) intake prevents
the development of HPT in patients (pts) with moderate and advanced
CRF. The aim of the present study was to assess in pts with advanced CRF
the mid-term effects of a low-Pi (5—7 mg/kg/day), low-Pr (0.3 g/kg/day) diet
providing 300 mg/day calcium (Ca) and supplemented with ketooacids, Ca
carbonate (400—800 mg/day) and vitamin D2 (1,000 lU/day) on phospho-
calcic metabolism. Twenty-nine pts with advanced CRF (isotopic GFR
13.7 4.5 mI/mm) were retrospectively selected, on the basis of a
follow-up of at least 2 years. At the start of the study, HPT was present
with increased PTH concentration (c.) (144 95 pg/mI), increased plasma
Pi (1.57 0.33 mmol/liter), and an increase in alkaline phosphatase
activity and osteocalcin c. PTH c. was correlated with Pi and Ca c. and
GFR. Pm and Pr restriction induced correction of HPT as early as 3 months
after the beginning of the diet. After 2 years, despite lower GFR (11.1
3.7 mI/mm, P < 0.0001), PTH was still low (88 57 pg/mI, P < 0.01), as
was Pi (1.32 0.24 mmol/liter, P < 0.001),with the total Ca being higher
(P < 0.01). No correlation was observed between GFR, Pi and PTH levels,
which were correlated only to Ca c. Variations in PTH were correlated
with variations of Ca and Pi, but not with variations of GFR. No variation
in calcitriol concentration was observed. The results of the present study
suggest that Pi and Pr restriction without calcitriol supplementation in pts
with advanced CRF may induce a lasting correction of HPT, potentially
mediated by the reduction of Pi and the increase of Ca concentrations.
HILDAJLIF secretion during infections in kidney transplant recipients.
D. More4 JL Taupin, C. Combe, E. Leguen L. Potaui N Gualde, and J.F.
Moreau, Hôpital Pellegrin, URA CNRS 1456, Bordeau. France. The cytokine
HILDA/LIF exerts a wide array of biological activities, some of them
implicated with inflammatory phenomena. It is secreted mostly by T lympho-
cytes and activated monocytes, which harbor high affinity receptors. Its
secretion is stimulated by IL-i. Besides, HILDA'LIF triggers hepatocytic
synthesis and release of acute phase proteins. Lastly, HILDA/LIF urinary
excretion is already known to increase during kidney transplant rejection. We
monitored HILDA/LIF urinary and blood levels in 21 kidney and 1 kidney
and pancreas transplant recipients weekly then monthly during the first year
posttransplant, using an ELISA developed in our laboratory. This sensitive
test combines two monoclonal antibodies recognizing two different epitopes
on the human soluble molecule. The threshold of detection is then around 80
pg/mi. In kidney transplant recipients without concomitant pathology,
HILDA'LIF usually remained below 80 pg/mi in blood, urinary excretion
being less than 300 ng/24 hr. During isolated infectious episodes, HILDA/LIF
urinary and blood levels can be summerized as follows:
Patients +
Patients + Patients + no increase
increased LIF increased LIF of LIF
Patients in urine in blood (blood or
Events N ng/24 hr pg/mi urine)
Urinary tract 8 N = 6 N = 3 N = 1
infections
m=2498
(300—11115)
m=627
322—980
Bronchitis 9 N = 6
m=820
(178—1250)
N = 4
m=287
(155—484)
N = 1
CMV 6 N=6
m=2904
(500—6269)
N=3
m=219
(140—264)
N=0
Orchi 2 N=1 N=2 N0
epidydimitis 2000 350—1000
Wound 2 N=2 N=1 N=0
Suppuration 1423—2993 340
Viral gastro- 1 N = 1 N = 1 N = 0
enteritis 2522 426
Esophageal 3 N = 2 N = 0 N 1
Candidiasis 368—600
HILDA/LIF urinary and blood levels usually decreased with the cure of
the infection. Taken together, these data indicate a strong correlation
between the development of infectious diseases and HILDA/LIF secre-
tion. It therefore emphasizes the involvment of these cytokines in clinical
inflammation and host defense mechanisms, even in immunocompro-
mized patients.
Granulocyte activation and adhesion molecules during hemodialysis
with cuprophan and a complement non-activating membrane. C. Combe,
M. Pourtein, V. de Precigout, A. Baquey, J.H. Bézian, and M Aparicio,
Service d'Hémodialyse et Laboratoire d'Immunologie, Hopital Pellegrin,
Bordeaux; France. Hemodialysis (HD) with complement (C) activating
membranes (mb) such as cuprophan (Cup) induces expression of the
granulocyte (PMN) adhesion receptor Mac-i (CDlib/CD18), while C
non-activating mb do not. Ten patients on regular HD were included in a
cross-over study. HD was performed for 2 weeks with Cup mb, and 2
weeks with polyamide (Poly) mb, a C non-activating mb. At the end of
each period, the following parameters were determined during an HD
session: C5a concentration by ELA, immunofluorescence flow-cytometiy
study of the expression by PMN of Mac-i, of LFA-i, and of the antigen
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recognized by MoF11 (AgMoF11), a monoclonal antibody which recog-
nizes activated PMN. Cup HD induced an increase in C5a concentration
and in the expression of Mac-i and AgMoF11 which were maximal after
15 minutes of HD, at the peak of neutropenia. Mac-i expression was
maintained throughout HD. Conversely, after peak expression, C5a and
AgMoF11 decreased, while PMN count increased to baseline values, Poly
HD did not induce variations in C5a concentration, in Mac-i or AgMoFil
expression. LFA-1 expression remained stable during HD with both mb
types. These results indicate that PMN activation as determined by
AgMoF11 expression during Cup HD correlates with leukopenia and C5a
concentration, while Mac-i expression is maintained throughout HD. Poly
HD induces neither PMN activation nor C activation.
The vasodilatory action of PTH-related protein in the isolated rabbit
kidney involves the nitric oxide syStem. T. Massfelder, U. Simeoni, C.
Saussine, and J-J. He/wig; Laboratoire de Physio/ogie Celiulaire Rénale,
Pavilion Poincaré Hospices Civils, Strasbourg, France, Previous studies
from this laboratory have shown that parathyroid hormone-related protein
(PTHrP) exhibits renovasodilatoiy properties. The mechanism underlying
this action remains unclear. The increasing number of compounds exert-
ing their vasodilatory action, through the stimulation of endothelial
constitutive NO-synthase and the central role of NO in renal hemody-
namics, prompted us to ask whether the renovascular effect of PTHrP
involves the nitric oxide system. To this end, we used the recirculating
isolated rabbit kidney perfused in the presence of 0.01 mmol/liter indo-
methacin (a cyclooxygenase inhibitor) and preconstricted with noradren-
aline (NA, 7.2 nmol/liter/min). Under control conditions, exposure to 1
moL/1iter acetylcholine (ACH, a NO-dependent renal vasodilator), 0.1
mmol/liter verapamil (VPL, a NO-independent renal vasOdilator) and 87
nmol/liter PTHrP-(i.34) reduced by 31, 71 and 43% the basal precon-
stricted perfusion pressure. The administration of 0.1 mmollliter N"'-
nitro-L-arginine methyl ester (L-NAME), known to competitively inhibit
NO-synthase, increased by 20% the preconstricted perfusion pressure.
Moreover, L-NAME decreased by 68% the vasodilatoiy response to ACH
but did not affect the VPL-induced vasodilation. In parallel, the response
to PTHrP was decreased by 44%. Both L-Arg at 1 mmol/liter, the
endogenous substrate of NO-synthase, and N'-benzoyl-L-Arg ethyl ester
at 1 mol/liter (BAEE), another substrate of NO-synthase, abolished the
inhibition induced by L-NAME on the vasodilatory responses to ACH and
PTHrP. It should be mentioned that unlike L-Arg, exposure to 1 mol/
liter of BAEE markedly and durably reduced by 57% the constriction
induced by NA and L-NAME. The results strongly suggest that the renal
vasodilatory action of PTHrP involves NO, presumably through stimula-
tion of constitutive NO-synthase. It is likely that cAMP production and/or
calcium entry blockade could account for the L-NAME-resistant renal
vasodilation of PTHrP. In support of this hypothesis, we reported
previously that PTHrP stimulates adenylyl cyclase in isolated renal micro-
vessels.
Heparin-associated thrombocytopenia in hemodialysis patients. B.
Page, A. Percheron, F. Jacobs, P. Urena, and J. Zingraff Department of
Nephrology, Necker Hospital, Paris, France. Heparin-associated thrombo-
cytopenia (HAT) is rarely observed in hemodialysis patients, despite the
use of heparin (H) for anticoagulation during hemodialysis (HD). We
report three patients who developed HAT after exposure to H during HD.
In all three cases H was used both for HD and to maintain catheter
patency. In one of the cases H was also administred for plasmapheresis.
Diagnosis of HAT was based on: exposure to heparin; severe and delayed
thrombocytopenia; Correction of thrombocytopenia after H discontinua-
tion; exclusion of another etiology for thrombocytopenia; clotting of
catheters, tubings, and dialyzers during HD or plasmapheresis; demon-
stration in plasma of a platelet activating factor (present in the IgU
fraction) using platelet aggregation tests. HAT requires discontinuation of
H in all cases. We used heparin-free hemodialysis with frequent saline
flushing and oral anticoagulation in two cases, Low molecular weight H
was used with success in 1 case because platelet aggregation tests using this
H were negative in vitro. The incidence of HAT in our HD unit is 0,5%.
We conclude that platelet count can be controlled in HD patients
especially during the first weeks of HD. HAT can be suspected when a
patient with a previously normal platelet count develops thrombocyto-
penia, with clotting of dialyzer, HD catheter or arteriovenous fistula.
H should be stopped as soon as the diagnosis is suspected. Alternatives
such as heparin-free HD with saline flushing, warfarin, or low molecular
weight H, can be employed with success.
Relationship between resistance to rHuEPO and kidney graft necrosis
in patients on hemodialysis. B. Page, Z. Zitouni, and .1. Zingraff Necker
Hospital, Paris, France. Kidney allografts are not routinely removed when
patients return to hemodialysis. However, when necrosis of the transplant
occurs, graft nephrectomy (TX) is required. The purpose of the present
study was to document resistance to rHuEPO in such cases. In the period
Jan 1, 1991 to Jan 1, 1993, 48 renal transplant recipients returned to
dialysis for chronic failure of their graft. Eleven of them underwent TX for
symptoms of necrosis of the graft such as fever, hematuria or massive
thrombosis at ultrasound examination. Resistance to rHuEPO was present
in 6 cases and preceded other symptoms. CRP was elevated in all cases.
The table summarizes hematologic data prior to and 1 month after TX:
Before TX 1 Month after TX P
Transfusion 6/6 pts 0/6 pts
dependency
Dosage of rHuEPO 189.4 73 189.4 73 NS
U/kg/week
Hemoglobin g/d/ 5.56 1.24 8.63 1.49 <0.01
Fibrinogen g/liter 7 0.93 4 1.94 <0.05
Plasma CRP mg/liter 59.2 30 18.1 15 <0.05
Conclusions: Resistance to rHuEPO related to the inflammatory syn-
drome of kidney graft rejection may precede acute symptoms of necrosis
and contribute to indication of TX. Correction of anemia occurred in all
cases after TX.
Cryptococcosis after renal transplantation: Report of three cases. B.
Page, C. Hennequin, A. Percheron, F. Jacobs, E. Thervet, C. Legendre, and
H. Kreis, Service de Transplantation Rénaie and Service de Microbiologic,
Hôpital Necker, Paris, France. Ciyptococcus neofonnans is a common cause
of fungal meningitis in immunocompromised patients with defects of
cell-mediated immunity, such as after organ transplantation, corticoste-
roid therapy, lymphoma, cancer or AIDS. AIDS is today the leading
predisposing factor to the disease. Three cases of cryptococcosis have been
identified in a 33 year experience with 1372 renal transplantations in 1216
patients. The three patients (all males, aged 43 to 56 years) developed
meningitis, associated with skin abscess in one case and fungemia in
another. In all three cases the infection appeared after long-term immu-
nosuppression, 5, 10 and 20 years after transplantation. In all cases
cerebrospinal fluid was clear and revealed lymphocytic pleocytosis, hypo-
glycorrachia, and an elevated protein level. India ink preparation was
positive in one case on direct examination, and capsular antigen was
detected in the two others. Definitive diagnosis was based on positive
culture of cerebrospinal fluid in 2 cases, culture of skin in 1 case, and blood
culture in 1 case. A combination of amphotericin B and 5 fluorocytosine
(N = 2) or fluconazole alone (N = 1) was used with success, without
relapse or recurrence, despite absence of long-term maintenance treat-
ment in 2 cases. In conclusion, cryptococcosis is rare in renal transplant
recipients in our experience. Headache and fever are the most common
symptoms. Examination of cerebrospinal fluid is the key to diagnosis.
Detection of capsular antigen is useful for diagnosis. With prompt therapy,
prognosis is good. Amphotericin B and 5 fluorocytosine remain the
standard antifungal therapy. Fluconazole appears to be a safe alternative
in renal transplant recipients due to its efficacy and absence of nephro-
toxicity.
Use of granulocyte macrophage colony-stimulating factor in leukopenic
renal transplant recipients. B. Page, M-P. Morin, M-F. Bruneel E. Thervet,
and C. Legendre, Department of Transplantation, Necker Hospital, Paris,
France. Leukopenia often occurs following renal transplantation. It is
usually secondary to drugs or infections, notably with cytomegalovirus
disease. Leukopenia can be associated with considerable morbidity and
mortality. It can preclude the use of immunosuppressive and anti-infective
agents because of their potential leukopenic side effects. It can lead to
early reduction or even withdrawal of immunosuppression in renal transplant
recipients and, subsequently, allograft rejection. The study of growth factors
for myeloid cells has created some novel approaches for the treatment of a
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number of diseases. Granulocyte colony-stimulating factor (G-CSF) and
granulocyte-macrophage colony-stimulating factor (GM-CSF) cause a rapid
rise in granulocytes when given to patients with normal bone marrow
function. They are also capable of raising blood granulocyte counts in patients
with bone marrow suppression caused by cytotoxic drugs or in patients with
disorders such as AIDS, aplastic anemia, myelodysplastic syndromes, cyclic
neutropenia and congenital agranulocytosis. An obvious potential use of
these hematopoietic growth factors is in the treatment of leukopenic organ
graft recipients. A major concern would be that such treatment might
exacerbate or even precipitate a rejection process. We report the use of
GM-cSF in 16 renal allograft recipients with leukopenia. Nonglycosylated
recombinant GM-CSF was obtained from E. coli transvected by human
GM-CSF gene. Written informed consent was obtained from all patients.
Patients were suffering from toxic neutropenia (neutrophils < 500/mm3) with
medullar hypocellularity on bone marrow aspiration, or leukopenia (neutro-
phils < 1000/mm3) with cytomegalovirus infection requiring gancyclovir
administration. GM-CSF was given subcutaneously at a daily dose of 2 to
5 pg/kg/day, according to renal function. In all cases, neutrophil counts
returned to normal levels within 1 to 4 days. In most, spectacular correction
was observed within 24 hours, with a single injection. Adverse events due to
GM-CSF at this dose were mild and easily managed (2 cases of bone pain
treated with paracetamol). One acute rejection episode was observed after
correction of leukopenia. On the basis of this study, it appears that GM-CSF
at a dose below 5 hg/kg/day is an effective treatment for renal transplant
recipients with leukopenia associated with CMV infection or toxic neutrope-
nia.
A cluster of pneumocystis carinii pneumonia in renal transplant
recipients. B. Page, C. Hennequin, E. Thervet, C. Legendre, and H. Kreis,
Service de Transplantation Rénale and Service de Microbiologie, Hôpital
Necker, Paris, France. In the 1980s, Pneumocystis carinii pneumonia (PCP)
emerged as the most common opportunistic infection complicating AIDS.
Renal transplant recipients (RTR) are also at risk for the development of
PCP, although this is not one of the more common infections encountered
after renal transplantation. In our unit, over a 6-month period [May-
October] in 1991, 7 renal transplant recipients developed PCP. This was a
significant change from our past experience with this disease, since only 2
cases had been observed over the preceding 5-year period. All patients
were HIV-negative. Since 1986 we have been using the same immunosup-
pressive protocols for renal transplantation. The seven patients received
OKT3 for the first fourteen days associated with low-dose steroids and
azathioprine, with a delayed introduction of ciclosporin in 6 patients.
Acute graft rejection episodes were treated with three intravenous injec-
tions of methylprednisolone. No prophylaxis for PCP was used. All
episodes of PCP were diagnosed by the presence of cysts of Pneumocystis
carinii in bronchoalveolar lavage (LBA) specimens. PCP occurred 140
(41—578) days after renal transplantation. Six patients experienced 1
episode of acute rejection in 3 cases and 2 episodes in 3 cases. All patients
were treated by trimethoprime-sulfamethoxazole (TMX). Outcome was
favorable in 5 cases, but 3 patients died from respiratory failure. When
survivors were compared with non-survivors, differences were observed in
Pa02 on admission (P < 0.05) in serum LDH increase (P < 0,05), and in
the use of mechanical ventilation (P < 0.05). Cytomegalovirus co-infection
was identified in 6 patients by isolation of the virus from blood and/or
LBA. Four bacterial co-infections were also observed. After institution of
routine prophylaxis with TMX, only one case of PCP has developed in a
patient who was not receiving adequate prophylaxis at the time PCP was
diagnosed. In 1987 a new medical unit devoted to AIDS patients was
located in the same building as our own unit. Each unit has its own medical
staff, but RTR and HIV-infected patients sometimes shared waiting rooms
and some of the rooms used for various treatments including pertamidine
aerosols. It is thus tempting to speculate that inter-human contamination
could have been a cause of PCP, as suggested earlier in Switzerland and
France. During the epidemic all infected RTR had been admitted in the
transplant unit, with overlapping stays, and thus transmission of the
disease between PCP RTR and noninfected RTR could have been
possible. In conclusion we suggest that: (1) HIV-infected patients and
transplant recipients should be treated in different areas, with separate
outpatient facilities. (2) Despite the lack of official guidelines, RTR with
active PCP should be isolated. (3) A routine prophylaxis with TMX in
RTR to prevent PCP should be used.
Specific labeling of urea channel by a photoactivatable inhibitor.
P. Neau, H. Lamotte, F. Degeilh, B. Rousseau, and P. Ripoche, Services de
Biologie Cellulaire et des Molecules Marquees, Département de Biologie
Cellulaire et Moléculaire, CE Saclay, France. Urea is well known to cross
the plasma membrane of different kinds of cells, such as mammalian red
cells, mammalian kidney cells or amphibian urinary bladder epithelial
cells, by a facilitated diffusion mechanism involving a membrane protein
which acts as a channel or a carrier. To gain insight into the molecular
characterization of this protein, one approach consists in isolating the
transporter by the use of specific and covalent markers. Then, a photoac-
tivatable urea analogue 1-(3-azido-4-chlorophenyl)-3-methyl-2-thiourea
([3H]-Me-ACPTU) was synthesized, tritiated (29 Cilmmol), and used as a
probe to photolabel the human red blood cell urea transporter. On
irradiation, [3H]-Me-ACPTU bound irreversibly white ghost membrane
proteins. SDS gel electrophoresis revealed radioactive incorporation in 5
major bands of 200, 110, 60,40 and 14 kDa. The labeling of the 40 and 60
kDa bands was partially prevented in the presence of high concentration
of other urea analogues such thiourea and 1-(3,4-dichlorophenyl) 2-thio-
urea. Photolabeling pattern obtained with white ghosts of the Kidd blood
group type Jk(a—,b—), known to be deficient in urea transport, showed a
lack of labeling at the level of the 40 kDa band. However, protective
experiments carried out with anti-Jka, anti-Jkb and anti-Jk3 antibodies
prevented radioactive incorporation only in the 60 Wa band and in the
110 Wa band on photolabeling pattern obtained with Jk(a+,b+) ghosts.
Finally, urea permeability of pink ghosts of blood type Jk(a+,b+)
measured in the presence of Jk3 antibodies exhibited 19% inhibition when
compared with control experiments. These results together support the
hypothesis that the Kidd antigen and the red blood cell facilitated urea
transporter could be the same protein. Urea permeability of frog urinary
bladder stimulated by 4.4 iO M oxytocin was irreversibly inhibited after
irradiation in the presence of Me-ACPTU, However, this permeability was
not affected by the presence of Jk antibodies suggesting either a species
specificity of the antibodies or a different protein responsible for the
ADH-sensitive urea transfer.
Antithymocyte globulins (ATG) contain antibodies against the fi
integrin molecule. M Ticchioni, G. Beniard-Pomier, M Deckert, E. Cas-
suto-Viguier, JR. Mondain, L. Van Eslande, J.C. Bendini, MA Rosenthal-
Allien, andA. Bernard, Laboratoire d'Immunologie, Hôpitalde l'Archet, and
Service de Néphrologie, Hopital Pasteur, Nice, France. Despite much
progress in the management of kidney graft patients, antithymocyte
globulins (ATG) are still widely used. Recently, it has been shown that
antilymphocyte globulins (ALG) contain antibodies against the lympho-
cyte functionantigen-1 molecule (LFA-1, CD11a/CD18) which belongs to
the 132 integrin subfamily. The /3 integrin molecule (CD29), expressed on
T cells, plays an important role as a co-stimulatoly molecule for T cell
activation and mediates both cell-cell and cell-matrix interaction. In order
to determine whether ATG also contain activity against the f3 molecule,
we used an adherence assay. Thymi were obtained from children under-
going cardiac surgery. Thymocytes, labeled with a fluorescent product
(BCECF) were incubated with ATG, rabbit immunoglobulins (RIG) or
PBS, washed, and allowed to adhere to fiat bottom wells coated with
CD11a or CD29 mAb for various intervals at 37°C. Cells remaining after
a final wash were quantified using the Cytofluor 2300 System (Millipore).
Results showed that specific binding to both CD1Ia and CD29 was
strongly inhibited by preincubation with ATG as compared to cells treated
with RIG. Moreover, adhesion of thymocytes on plates coated with ATG
was also weakly inhibited by preincubation with CD11a, CD29 and CD11a
+ CD29 mAb. Taken together, these data may suggest that antibodies
against the 13 integrin are present in ATG.
Urinary bladder immunolocalization of renal kallikrein in rat. C Orfila,
G. Bompaiz JC. Lepert, J.M Suc, andJi'. Girolami, INSERMCJF9I-O7and
CJF 92-05, Service de Néphrologie, CHU Ranguei4 Toulouse, France. Renal
kallikrein is a serine protease synthesized by the connecting tubule cells of the
distal nephron and secreted in the urine. The presence of kallikrein in urine
raises questions about a possible physiological role of this enzyme at the
urinary level. For this reason, the presence of kallikrein in rat urinary tract was
investigated. We have already demonstrated the presence of a kallikrein-like
substance in rat ureter. In the present study, we searched for the presence of
this enzyme at other levels of the unnaiy tract, by immunohistochemical
techniques for light and electron microscopy, using an antibody against rat
urinary kallikrein. By light microscopy, kallikrein was localized at the level of
lamina propria, composed of a dense layer of collagenous connective tissue
and situated between the transitional epithelium and the muscularis. Weaker
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labeling was present in the smooth muscle layer. By electron microscopy,
marked labeling was demonstrated in organelles present in the cytoplasm of
fibroblasts in connective tissue of the lamina propria and penetrating into
layers of smooth muscle. Immunoreactivity was observed along the endoplas-
mic reticulum, in free polyribosomes, in cisternae of Golgi apparatus and
surrounding vesicles. No labeling was observed in other subcellular elements
or other parts of the wall bladder. Immunoreactive kallikrein was also
quantified in urinary bladder extracts by radioimmunoassay. The concentra-
tion was 11.6 1.4 ng of kallikrein/100 mg of tissue. In conclusion, in this
study we reported the presence of immunoreactive kallikrein in the wall of rat
urinary bladder, demonstrated by imrnunocytochemistty and measurement of
immunoreactive kallikrein by radioimmunoassay. The continuity of the
presence of kallikrein along the urinaly tract from the kidney, the ureter to
the urinaiy bladder gives new indications concerning the significance of the
physiological role of the kallikrein-kinin system in renal physiology.
Renal handling of amino acids during elicitation of the renal functional
reserve. I. Tack, M. Moussa, T Tran-Van, F. Praddaude, and J.-L. Ader,
Laboratoire d'Explorations Fonctionnelles Rénales et Metaboliques, CJF
Inserm 92-05 and Laboratoire de Biochimie H, CHU Rangueil, Toulouse,
France. The aim of this study was to examine the relationship between
changes in glomerular filtration rate (GFR) and in amino acid (AA)
transport during elicitation of the renal functional reserve (RFR) in 12
healthy volunteers. GFR (clearance of inulin) and plasma and urine
concentrations of amino acids (ion exchange chromatography) were
measured prior to (Ti), at the end (T2), and 3 hours after completion (T3)
of a 3-hour i.v. infusion of a mixture of 20 I-amino acids (Azonutril 25®, 4.5
mg AA/kglmin). GFR was 116.0 14.3 ml/min/i.73 m2 at Ti and
increased to 135.2 i0.9 ml/min/1.73 in2 at T2 (m SD, P < 0.001).
Meanwhile, total amino acidemia (tAA) and total amino aciduria also
significantly increased from 2.01 0.44 to 6.21 1.01 mmol/liter and from
0.93 0.3 to 8.05 3.82 mmol/liter, respectively (P < 0.001). Clearance
(C ml/inin/1.73 m2), fractionnal excretion (FE %) and absolute reabsorp-
tion (AR mol/min/i.73 m2) were calculated for tAA and for some
notable AA: taurine (TAU) absent from the infusion; arginine (ARG), an
Azonutril® component classically capable of eliciting RFR; and leucine
(LEU), another Azonutril® component uncapable of eliciting RFR.
TI
C FE AR
tAA
TAU
ARG
LEU
2.17 0.72
10.60 5.20
0.14 0.15
1.04 0.58
1.87 0.55
9.30 4.40
0.12 0.13
0.91 0.57
2288 56965 2
69 25
99 26
T2
C FE AR
tAA
TAU
ARG
LEU
6.11 1.62"
15.20 6.80
3.97 3161,
1.24 0.63
4.54 1.26"
11.50 5.30
2.98 249b
0.91 0.43
8050 1766"
83 301.
949 217"
636 141C
Differences between T2 and Ti,
"P <0.001)
paired t-test: P < 0.05, bp < 0.01;
In addition, GFR was directly correlated to both tAA and ARG concen-
trations in plasma at T3, while amino acidemia was still slightly increased,
but not when amino acidemia was low (Ti) or high enough to exceed the
tubular transport capacity (T2). No significant correlation was observed
between GFR and TAU or LEU concentration. Finally, amino acid
loading, resulting in acute glomerular hyperfiltration and increased abso-
lute and fractional AA excretion, also induced an increase in the tubular
absolute reabsorption of amino acids whatever their ability to elicit RFR.
Furthermore, GFR is directly dependent on tAA and ARG plasmatic
levels after AA infusion. These results suggest that amino acid tubular
transport may determine, at least in part, GFR alterations in humans.
Appearance of antibodies after intradernial injection of recombinant
hepatitis B vaccine in hemodialysis patients nonresponsive to the i.m.
route. J.M. Powç, S. Ranger-rogez, C. Lagarde, F. Denis, and C. Leroux-
Robert, Service de Néphrologie et Laboratoire de Virologie, C.H. U. Du-
puytren-2, Limoges, France. The response to indradermal (i.d.) injection of
recombinant hepatitis B vaccine (r-VHB) was studied in 14 hemodialysis
patients (HDP) (mean age 60.7 3.6 years) nonresponsive to the i.m.
route. Five g of r-VHB were administered every 2 weeks (maximum 70
j.g r-VHB) until the appearance of anti-HBs antibodies 230 mUl/mi.
Anti-HBs antibody levels were determined after the third i.d, injection and
then eveiy 2 weeks. Antibodies were found in 10 HDP (71%). Among
them 7 had developed antibodies before the sixth i.d. injection. Two I-IDP
had developed antibody titers n 1000 mUI/ml after 3 or 4 i,d. injections.
Eight of the 10 responsive patients were monitered at least 2 months after
the i.d. injections were discontinued. When the i.d. injections were
discontinued the mean antibody level was 440 131 mUl/mI, 1 month
later 338 ill mUl/mI and 2 months later 304 ill mUI/ml. Among the
4 HDP nonresponsive to the id. route, two had been treated by Endoxan
for Wegener's granulomatosus. The age (P < 0.5) and the sex of HDP,
hemodialysis duration (49 vs. 45.5 months, P < 0.8), hemoglobin or
erythropoietin treatment did not seem to play a role in the appearance of
antibodies. In conclusion, id injection of r-VHB resulted in the appear-
ance of antibodies in a substantial number of HDP nonresponsive to the
i.m. route, but the duration of this response remains to be determined.
Aldosterone interaction on Na transport and Cl permeability in
distal cultured (A6) kidney cells. 0. Devuyst, V. Beaujean and J. Crabbé,
Depis. of Nephrology and Physiology, University of Louvain Medical School,
Brussels, Belgium. The A6 cell line, derived from the distal part of Xenopus
laevis nephron, is an established model for studying the principal cells of
the mammalian collecting duct and the mechanisms underlying the
stimulation by aldosterone of Na reabsorption, Yet, little is known about
Cl permeability of A6 cells and the influence exerted on this parameter
by aldosterone. Short-circuit current (I,) and transepithelial conductance
(G,) were measured in A6 monolayers incubated overnight with or without
aldosterone (0.1 j.M). Paracellular "shunt" conductance (Gh, that is
residual G, during exposure to apical 100 M amiloride) was determined,
as well as cell conductance (GclI = G, — G1,). These parameters were
correlated with Na and Cl influxes (JNa and measured by means of
22Na and 36Cl. The data (x suM) summarized below indicate that, unlike
1Na' c1 is not stimulated by aldosterone in A6 monolayers.
Control
(N=3i)
Aldo
(N=20) P
I, pA cm2 3.5 0.3 11.4 0.6 <0.0001
G, mS cm2 0.20 0.01 0.26 0.02 <0.001
G011 mS cm2
Gh mS cm2
0.07 0.01
0.13 0.01
0.12 0.01
0.14 0.01
<0.0005
NS
1N pEq cm2 sec'
J,pEqcm2'sec'
53 629 3 141 1432 7 <0.0001NS
There is no conductive counterpart to J1, as I fell to zero when a
chemical driving force for Cl influx was created in absence of Na1,
transport. These data show that the aldosterone-induced increase in G,
results solely from an increase in G1,,,, expected in view of increased Na
reabsorption (monitored by I, and JN). Unlike the amphibian skin,
aldosterone has no effect on G,1, in A6 monolayers and no conductive Cl
pathway appears to be operative in these cells. These findings are probably
related to the homogeneity in terms of cell type of the A6 monolayers;
they present an argument in favor of a distinct cellular counterpart for the
C1 pathway in epithelia such as amphibian skin, where cell heterogeneity
is encountered.
Progression of renal failure in autosomal polycystic kidney disease
according to the gender of the patient and the vector parent. J.L.
Christophe, J.F. Perez-Oliva-Diaz, D. Chauveau, and J.P. Grunfeld, Dept. of
Nephrology Hôpital Necker, Paris, France, Certain studies have suggested
that the progression of renal failure in autosomal dominant polycystic
kidney disease (ADPKD) is influenced by the gender of the parent who
transmitted the disease (vector parent). The patient gender could be
another determining factor. To test these hypotheses, we made a retro-
spective study of 61 dialysis patients for whom a diagnosis of ADPKD had
been made and for whom the vector parent was known, Using the family
trees of these 61 families we retained 80 subjects for whom both the
gender of vector parent and the age at end-stage renal disease (ESRD)
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were known. There were 37 men and 43 women who were divided into the
following groups: female subject and mother vector: 25 (group A); female
subject and father vector: 18 (group B); male subject and mother vector:
15 (group C); male subject and father vector: 22 (group D). Results are
shown in the table. Age at ESRD differs significantly between male
(groups C + D) and female (groups A + B) subjects. No significant
difference is found on comparing groups B + D (father vector) with
groups A + C (mother vector). When the four groups are compared with
each other, group B alone is significantly different from groups C and D
(ANOVA, Newman-Keuls test) reflecting the role of the patient gender.
Groups
A B C D
Number of 25 18 15 22
patients
Age at ESRD 52.5 8.8 58.9 7 49.3 9 50.5 9.9
(mean SD)
A + B (55.2 8.6) vs. C + D (50.1 9.4): P = 0.013.
A + C (51.3 8.9) vs. B + D (54.3 9.6): nonsignificant.
B vs. C: P < 0.01.
B vs. D: P < 0.05.
In conclusion, this study supports the idea that progression of renal failure
in ADPKD is influenced by the sex of the patient but not by the sex of the
parent responsible for transmission of the disease.
Epidemiologic aspects of nephropathies associated with AIDS in trop-
ical regions. C. Assambo-Kieli, YF. Obengui, CHU Brazzaville, Congo.
From August 1, 1989 to April 30, 1992, among the 727 patients admitted
into the Department of Nephrology-Hemodialysis, 77 presented clinical
and biological signs of AIDS. We analyzed 55 files of these patients with
renal diseases as well as AIDS, in order to evaluate their incidence and
assess the impact on morbidity and evolution of this association. The
studied population was as follows: 35 men, 20 women aged from 16 to 71
years old, mean range 35 years. Venereal was the major way of transmis-
sion. Two patients had received blood transfusions. Positive AIDS diag-
nosis was based on standard criteria of WHO. The confirmation of HIV
infection in all cases was performed by ELISA and/or Western Blot.
Associated opportunistic affections probably participating in the renal
lesions in our cases were as follows. Intestinal parasitoses: 10 cases
(amibiasis 5 cases, tricophalosis 4 cases, ascaridiosis 1 case), viral infection
5 cases, (hepatitis B 3 cases, herpes zoster 2 cases), pulmonary tuberculosis
5 bacterial affections 7 cases (streptococcus 5 cases, salmonelosis 1 case,
syphilis 1 case). The renal lesions were grouped as follows. Group I: simple
urinary abnormalities (proteinuria 0.30 g to 1 g/day, 5 cases (9.1%);
macroscopic hematuria, 2 cases (3.6%). Group II: renal suppuration, 4
cases (7.3%) (renal abscess, perirenal phlegmon, pyelonephritis). Group
III: acute nephropathies (AGN) 1 case (1.8%), APN 1 case 1.8%,
functional ARF 10 cases (18.2%). Group IV: chronic nephropathies
(CGN syndrome) 4 cases (7.3%), nephrotic syndrome, 15 cases (27.3%).
Group V: chronic renal failure (CRF) 13 cases (23.6%). The optical
morphologic aspects of 9 renal biopsies of patients presenting nephrotic
syndrome were as follows: minimal glomerular lesions 3 cases, segmentary
and focal hyalinosis 2 cases, proliferative membranous glomerulonephritis
3 cases, proliferative endocapillary glomerulonephritis 1 case. All patients
received symptomatic treatment. Five patients with CRF were treated by
ACPD, and 30 patients died during hospitalization [hence 4.1% of all
in-patients; 33.7% of all diseases during the period of study (89 deaths),
and 54.5% of the studied cases]. The observations suggest that the
association AIDS nephropathy increases the severity of prognosis of renal
diseases in tropical regions, particularly in Congo. The etiopathogenic
correlation was not established in our study, however, because it is a
retrospective analysis.
Optical microscopy in early glomerulonephritis of the child in the
Congo. C. Assambo-Kieli, G. Moyen, J. Kokolo, B. Lomani-Luakabwanga,
and S. Nzingoula, CHU Brazzaville, Congo. This study has been done with
the objective of analyzing the incidence, the intensity and the evolution of
various lesions of early glomerular nephropathies of the child in the
Congo and investigating their characteristics. Fifteen kidney biopsies have
been done at the Brazzaville CHU to 9 boys and 6 girls aged 2 to 15. The
study period spans January 1988 to December 1991, 4 years hence. The
biopsy indications were the following:
12 nephrotic syndrome cases
2 recent cases of kidney insufficiency
1 case of chronic glomerulonephritis syndrome
The observed morphologic characteristics were as follows:
Glomerulonephritis with minimal glomerular
lesions (MGL)
Glomeruloscierosis (GS)
Segmentary and focal hyalinosis (SFH)
Global sclerosis (GS)
Proliferative endo- and extracapillary
glomerulonephritis (PEEG)
Proliferative endocapillary glomerulonephritis
(PEG)
Segmental and focal endotheliomesangial
Exudative endocapillary
Membranoproliferative glomerulonephritis
(MPGN)
The spontaneous evolution and/or with treatment is divided with regard
to the morphologic characteristics:
Morphologic
characteristics
Mid-term
evolution Long-term evolution
6 MGL 3 remissions 3 recurrences
4 GS 4 IRC 2 DPCA 1 death
2 PEEG 2 IRC 1 DPCA 1 death
2PEG 2IRC 1GR
1MPGN 1IRC -
In conclusion, one is struck by the incidence of the advanced lesions: 60%
cases; 9 patients in chronic kidney insufficiency (CM) including 3 contin-
uous ambulatory peritoneal dialysis (CAPD), 1 kidney grafting (KG), and
two deaths during hospitalization.
A multicentric prospective controlled trial comparing subcutaneous
and intravenous routes of recombinant erythropoietin administration
efficiency for chronic hemodialyzed patients on maintenance phase of
treatment. J.S. Virot, G. Janin, J. Guillaumie, P. Michel, P. Dubot, V.
Monnier-Zeller, P. Brunet-Lecompte, D. Chevet, and G. Rifle, et les néph-
rologues de Bourgogne. Service de Néphrologie-Réanimation CHRU Dijon,
Service de Néphrologie, CHMacon, Service de Néphrologie CHDoZe, Service
de Néphrologie CH Sens, Service de Nephrologie CH Chalons/Saone,
Laboratoire de Biochimie CHRU Dijon, Laboratoire d'Infonnatique Médi-
cale CHRU Dijon, France. The subcutaneous (s.c.) route for administration of
recombinant human erythropoietin (rHuEPO) may have some advantages
over the intravenous (i.v.) one for patients treated by maintenance hemodi-
alysis: better tolerance and lower doses. However, some trials are disputable
because they include the initiation phase of treatment before dose stabiliza-
tion. For these reasons, we have chosen to compare the dosages of both these
routes of administration in the maintenance phase of treatment and to grade
threm according to their preliminary needs. Patients and methods: We
included 49 hemodialyzed patients (3 times a week) already treated by
rHuEPO (Eprex*, CILAG) for at least 6 months (36 by iv. and 13 by s.c.). An
initial grading distinguished: 8 high (>150 p1kg/week), 12 middle (between
100 and 150 p1kg/week) and 29 low consumers (<100 pJkgeek). In each of
the 3 strata, the administration route of therapy was randomly allocated.
Twenty-five patients entered the i.v. group (among whom 5 were previously
treated by the s.c. route) and 24 patients entered the s.c. group (among whom
16 were previously treated by the i.v. route). At the beginning of the trial,
means were 106 p1kg/week in the iv. group versus 98 p1kg/week in the s.c.
group (P = NS). The average of hemoglobin, endogen secretion of EPO and
resistance factors of this treatment (iron, folic acid, vit. B12, aluminum and
parathormone) were similar in both groups. During the study dosages were
adaptated to obtain a hemoglobin level between 90 and 110 glliter. On the
16th week the mean dosages in both groups were compared by variance
analysis and Kruskal-Wallis test. Results: rHuEPO consumption: At the end
of the trial the mean dosage was significantly lower (P = 0.02) in the s.c. group
6 cases 40%
4 cases 26.7%
2 cases
2 cases
2 cases 13.3%
2 cases 13.9%
1 case
1 case
1 case
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(84 1ijkg/week) versus the Lv, group (112 zlkg/week), globally for the 3 strata.
Then separately analyzing each stratum, we noted that the decrease of dosage
using s.c. was significant only for the high and middle strata. There was no
significant difference for the low consumers. Side effects: A woman died from
myocardial infarction in the s.c. group; there was no argument for responsi-
bility of the treatment. Three patients had severe hypertension (2 is. vs. 1 s.c.,
P = NS). Six fistula thromboses were observed (5 i.v. vs. 1 s.c., P = 0.09).
Cutaneous pain at s.c. injection site was frequentely observed at the beginning
of the treatment but disappeared for the majority of the patients at the end of
the study. Arthralgias, flush syndrome and hyperkaliemia were reported only
in the i.v. group. Conclusions: (1) Our trial confirms that maintenance phase
of treatment by rHuEPO is more effective when using the s.c. mute of
administration especially for high consumers. (2) The severe side effects
occurred less frequently when using s.c. (3) We suggest replacing the is. route
of rHuEPO administration by s.c. route especially if the patients previously
had high consumption.
